Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L1-79 in adolescents and young adults with ASD
NCT05067582Phase 2Completed
- Sponsor
- Yamo Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of L1-79 in Autism Spectrum Disorder (ASD), sponsored by Yamo Pharmaceuticals. Started Jan 2022; status: completed.
02
Drugs
L1-79
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05067582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067582.